期刊文献+

基于磁共振图像的脑瘤MGMT表达状况检测算法 被引量:2

Detecting MGMT expression status of glioma with magnetic resonance image
下载PDF
导出
摘要 针对脑胶质瘤的O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)表达状况检测受主观影响的问题,以中国脑胶质瘤患者的磁共振图像(MRI)为研究对象,提出一种包括特征提取、特征优化和模式分类的图像处理方法.利用图像的灰度共生矩阵、灰度-梯度共生矩阵和二维离散正交S变换(2D-DOST)提取肿瘤病变区域的纹理特征,结合环形增强和年龄特征构成初始特征集.将k最邻近法(KNN)与支持向量机(SVM)结合,进行特征优化.使用留一交叉检验法(LOOCV),将最优特征集进行SVM分类.分别对25位脑胶质瘤患者的T1加权、T1增强和FLAIR序列的磁共振图像进行分析.结果表明,该算法能够降低特征集的冗余程度,克服小样本分类困难,准确有效地检测MGMT表达状况. In order to overcome the deficiency of strong subjectivity in detecting O6-methylguanine-DNA methyltransferase(MGMT) expression of gliomas,an image processing method was proposed to analyze the magnetic resonance images(MRI) of Chinese glioma patients.The method included feature extraction,feature optimization and pattern recognition.Gray co-occurrence matrix,gray level-gradient co-occurrence matrix and two-dimensional discrete orthogonal S-transform(2D-DOST) were utilized to extract the texture features in the tumor area.Ring enhancement and age were also added in the initial feature set.Then k-nearest neighbor(KNN) and support vector machine(SVM) were combined to search optimal features.The optimal feature set was classified by SVM in a leave-one-out cross validation strategy(LOOCV).T1-weighted,T1-enhanced and FLAIR MRI of 25 glioma patients were analyzed.Results show that the algorithm can reduce the redundance of feature set,overcome the difficulty of small sample classification and identify the status of MGMT expression accurately and effectively.
出处 《浙江大学学报(工学版)》 EI CAS CSCD 北大核心 2012年第1期170-176,共7页 Journal of Zhejiang University:Engineering Science
基金 国家自然科学基金资助项目(60772092)
关键词 脑胶质瘤 图像分析 特征提取 支持向量机(SVM) glioma image analysis feature extraction support vector machine(SVM)
  • 相关文献

参考文献21

  • 1HEGI M E, DISERENS A C, GORLIA T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma [J]. New England Journal of Medicine, 2005, 352(10) : 997 - 1003.
  • 2孙彦辉,张亚卓,王忠诚,孙梅珍,赵东海.MGMT在脑胶质瘤组织中的表达及其与患者生存期的关系[J].癌症,2004,23(9):1052-1055. 被引量:36
  • 3SEIDAL T, BALATON A J, BATTIFORA H. Interpretation and quantification of immunostains [J]. The American Journal of Surgical Pathology, 2001, 25 (9) : 1204 - 1207.
  • 4MOSKALUK C A. Standardization of clinical immunohistochemistry [J]. American Journal of Clinical Pathology, 2002, 118(5): 669-671.
  • 5BRUZZONE M G, EOLI M, CUCCARINI V, et al. Genetic signature of adult gliomas and correlation with MRI features [J]. Expert Review of Molecular Diagnostics, 2009, 9(7): 709-720.
  • 6LEVNER I, DRABYCZ S, ROLDAN G, et al. Predicting MGMT methylation status of glioblastomas from MRI texture [C]// Proceedings of the 12th International Conference on Medical Image Computing and Computer- Assisted Intervention: Part II. London: Springer, 2009: 522 - 530.
  • 7DRABYCZ S, ROLDAN G, DE ROBLES P, et al. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging [J]. Neurolmage, 2010, 49(2) : 1398 - 1405.
  • 8WIENCKE J K. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-Methylguanine-DNA-Methyltransferase [J]. Cancer Epidemiology Biomarkers and Prevention, 2005, 14(7): 1774-1783.
  • 9ZHANG J, TONG L Z, WANG L, et al. Texture analysis of multiple sclerosis: a comparative study [J].Magnetic Resonance Imaging, 2008, 26(8) : 1160 - 1166.
  • 10ROLHION C, PENAULT-LLORCA F, KEMENY J L, et al. O6-methytguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation [J]. International Journal of Cancer, 1999, 84 (4) : 416 - 420.

二级参考文献16

  • 1章毓晋.图像处理和分析[M].清华大学出版社,1999,3..
  • 2Balana C, Ramirez JL, Taron M, et al. O6 methylguanine DNA methyltransferase Methylation in Serum and Tumor DNA Predicts Response to 1,3 Bis(2 Chloroethyl) 1 Nitrosourea but not to Temozolamide Plus Cisplatin in Glioblastoma Multiforme [J]. Clin Cancer Res, 2003, 9(4): 1461- 1468.
  • 3Andratachke N, Grosu AL, Molls M, et al. Perspectives in the treament of malignant gliomas in adults [J]. Anticancer Res, 2001, 21(5):3541- 3550.
  • 4Silber JR, Bobola MS, Ghatan S, et al. O6 methylguanine DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics [J]. Cancer Res, 1998, 58(5): 1068- 1073.
  • 5Silber JR, Blank A, Bobola MS, et al. O6 methylguanine DNA methltransferase deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent based chemotherapy [J]. Clin Cancer Res, 1999, 5(4): 807- 814.
  • 6Nutt CL, Loktionova NA, Pegg AE, et al. O(6) methylguanine DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes [J]. Carcinogenesis, 1999, 20(12): 2361- 2365.
  • 7Bobola MS, Berger MS, Ellenbogen RG, et al. O6 Methylguanine DNA methyltransferase in pediatric primary brain tumors: relation to patients and tumor characteristics [J]. Clin Cancer Res,2001,7(3):613- 619.
  • 8Esteller M, Garcia Foncillas J, Andion E, et al. Inactivation of the DNA Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents [J]. N Engl J Med, 2000, 343(23):1350- 1354.
  • 9Watanabe T, Nakamura M, Kros JM, et al. Phenotype versus genotype correlation in oligodendrogliomas and low grade diffuse astrocytomas [J]. Acta Neuropathol (Berl), 2002,103(3):267- 275.
  • 10Nakamura M, Watanabe T, Yonekawa Y, et al. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→ A:T mutations of the TP53 tumor suppressor gene [J]. Carcinogenesis, 2001, 22(10):1715- 1719.

共引文献101

同被引文献51

  • 1郭素红,卢洁,于常海.生物标记检测在神经胶质瘤诊断中的研究进展[J].吉林医药学院学报,2009,30(6):352-357. 被引量:2
  • 2周东海,何宁,黄进,张静,赵志文,李炳翠,李刚,位春萍.幕上星形细胞瘤瘤周水肿MRI表现与P53蛋白的对照研究[J].中国临床医学影像杂志,2007,18(3):167-170. 被引量:2
  • 3Boudreau CR, Yang I,Liau LM. Gliomas : advances in mo-lecular analysis and characterization [ J]. Surgical Neurology,2005,64(4) : 286-294.
  • 4Saitta L, Heese 0,Forster AF, et al. Signal intensity in T2'magnetic resonance imaging is related to brain glioma grade[J]. European Radiology, 2011, 21(5) : 1068-1076.
  • 5Arvinda H, Kesavadas C, Sarma P, et al. Glioma grading:sensitivity,specificity,positive and negative predictive valuesof diffusion and perfusion imaging[ J]. Journal of Neuro-On-cology, 2009, 94(1); 87-96.
  • 6Brown R, Zlatescu M, Sijben D, et al. The Use of MagneticResonance Imaging to Noninvasively Detect Genetic Signaturesin Oligodendroglioma[ J]. Clinical Cancer Research,2008,14(8) : 2357-2362.
  • 7Drabycz S, Rolddn G, de Robles P, et al. An analysis of im-age texture, tumor location,and MGMT promoter methylationin glioblastoma using magnetic resonance imaging[ J]. Neuro-Image, 2010, 49(2) : 1398-1405.
  • 8Levner I, Drabycz S,Roldan G, et al. Predicting MGMTmethylation status of glioblastomas from MRI texture[ C]. In:Proceedings of the 12th International Conference on MedicalImage Computing and Computer-Assisted Intervention : PartII. London, UK: Springer Press, 2009 : 522-530.
  • 9Law M, Yang S, Babb JS, et al. Comparison of cerebralblood volume and vascular permeability from dynamic suscep-tibility contrast-enhanced perfusion MR imaging with gliomagrade [ J] . American Journal of Neuroradiology,2004,25(5): 746-755.
  • 10Kono K, Yuichi I,Keiko N, et al. The role of diffusion-weighted imaging in patients with brain tumors [ J]. AmericanJournal of Neuroradiology, 2001,22(6) : 1081-1088.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部